{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:24:53Z","timestamp":1768879493788,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB Pharma Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00807-0","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T02:13:09Z","timestamp":1762395189000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-per-Responder Analysis of Bimekizumab (IL-17A\/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-1321","authenticated-orcid":false,"given":"Jorge","family":"Mestre-Ferrandiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoana","family":"Ivanova-Markova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Maratia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"10136","key":"807_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"2","key":"807_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101670","volume":"35","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S, et al. Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101670.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"807_CR3","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/rheumatology\/keae198","volume":"63","author":"S Lembke","year":"2024","unstructured":"Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis. Rheumatology. 2024;63(12):3211\u201320.","journal-title":"Rheumatology"},{"issue":"8","key":"807_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for research and assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"807_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol Hoboken NJ. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"807_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"key":"807_CR7","unstructured":"European Medicines Agency. European Public Assessment Report: Bimzelx\u00ae (hidradenitis suppurativa). 2024."},{"issue":"7","key":"807_CR8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","volume":"63","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gladman DD, Merola JF, Nash P, Grieve S, Laliman-Khara V, et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology. 2024;63(7):1779\u201389.","journal-title":"Rheumatology"},{"issue":"3","key":"807_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40744-024-00652-7","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, et al. Comparative effectiveness of bimekizumab and secukinumab in patients with psoriatic arthritis at 52 weeks using a matching-adjusted indirect comparison. Rheumatol Ther. 2024;11(3):817\u201328.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"807_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s40744-024-00705-x","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Taieb V, et al. Comparative effectiveness of bimekizumab and ustekinumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatol Ther. 2024;11(5):1413\u201323.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"807_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s40744-024-00706-w","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, et al. Comparative effectiveness of bimekizumab and risankizumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatol Ther. 2024;11(5):1403\u201312.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"807_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40744-024-00659-0","volume":"11","author":"RB Warren","year":"2024","unstructured":"Warren RB, McInnes IB, Nash P, Grouin JM, Lyris N, Willems D, et al. Comparative effectiveness of bimekizumab and guselkumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatol Ther. 2024;11(3):829\u201339.","journal-title":"Rheumatol Ther"},{"issue":"7","key":"807_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"R Burgos-Pol","year":"2016","unstructured":"Burgos-Pol R, Mart\u00ednez-Sesmero JM, Ventura-Cerd\u00e1 JM, El\u00edas I, Caloto MT, Casado M\u00c1. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577\u201390.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"807_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s40744-023-00602-9","volume":"10","author":"N Frede","year":"2023","unstructured":"Frede N, Hiestand S, Schauer F, Endres D, Tebartz van Elst L, Zeisbrich M, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther. 2023;10(6):1655\u201368.","journal-title":"Rheumatol Ther."},{"key":"807_CR15","unstructured":"General Council of Pharmaceutical Associations. BOT PLUS. Base de datos de informaci\u00f3n sanitaria de medicamentos y productos de parafarmacia. [cited 2025 Apr 15]. https:\/\/botplusweb.farmaceuticos.com\/"},{"key":"807_CR16","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Agencia Estatal Bolet\u00edn Ofical del Estado. [cited 2016 May 20]. https:\/\/www.boe.es\/diario_boe\/txt.php?id=BOE-A-2010-8228."},{"key":"807_CR17","unstructured":"Ministry of Health. BIFIMED: Buscador de la informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos. [cited 2025 Apr 15]. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do."},{"key":"807_CR18","unstructured":"Spanish Agency of Medicines and Medical Devices. CIMA. Centro de Informaci\u00f3n de medicamentos. 2024 [cited 2025 Mar 12]. https:\/\/cima.aemps.es\/cima\/publico\/home.html."},{"issue":"Suppl 10(Suppl","key":"807_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/acr.24242","volume":"72","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res. 2020;72(Suppl 10(Suppl 10)):82\u2013109.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"807_CR20","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(21)00349-0","volume":"4","author":"J Day","year":"2022","unstructured":"Day J, Antony A, Tillett W, Coates LC. The state of the art\u2014psoriatic arthritis outcome assessment in clinical trials and daily practice. Lancet Rheumatol. 2022;4(3):e220\u20138.","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"807_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3899\/jrheum.170449","volume":"45","author":"L Gossec","year":"2018","unstructured":"Gossec L, McGonagle D, Korotaeva T, Lubrano E, de Miguel E, \u00d8stergaard M, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2018;45(1):6\u201313.","journal-title":"J Rheumatol"},{"issue":"1","key":"807_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000415","volume":"3","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017;3(1):e000415.","journal-title":"RMD Open"},{"key":"807_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19831151","volume":"11","author":"L Bessette","year":"2019","unstructured":"Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, et al. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational F\u03b1st-CAN study. Ther Adv Musculoskelet Dis. 2019;11:1759720X19831151.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"807_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"807_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40744-017-0070-6","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A. Comparative effectiveness of Adalimumab versus Secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison. Rheumatol Ther. 2017;4(2):349\u201362.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"807_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/vaccines10050646","volume":"10","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Geat D, Maurelli M, Degli Esposti L, Bellinato F, Girolomoni G. Cost per responder analysis of secukinumab versus adalimumab in the treatment of psoriatic disease. Vaccines. 2022;10(5):646.","journal-title":"Vaccines"},{"key":"807_CR27","unstructured":"Arganda C. Precios notificados: cada a\u00f1o hay m\u00e1s y con mayor diferencia sobre el real. Diariofarma. 2019 [cited 2024 Oct 25]. https:\/\/diariofarma.com\/2019\/02\/12\/precios-notificados-cada-ano-hay-mas-y-con-mayor-diferencia-sobre-el-real."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00807-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:22Z","timestamp":1768834342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00807-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00807-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jorge Mestre-Ferr\u00e1ndiz: Consultant fees from UCB; Victoria Navarro-Comp\u00e1n\u00a0has received consulting fees, research or institutional support and educational grants from:\u00a0AbbVie,\u00a0Alfasigma, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Johnson & Johnson,\u00a0Moonlake, MSD, Novartis, Pfizer, Roche, UCB; Yoana Ivanova-Markova and Almudena Gonz\u00e1lez-Dominguez: Employees of Weber; Stefano Maratia: Employee of UCB. Almudena Gonz\u00e1lez-Dom\u00ednguez changed affiliation during the completion of this manuscript. Her current affiliation is Lead, Health Economics & Market Access, Theorema4h, Madrid, Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Our study did not require approval from any ethics committee. Applying the Helsinki Declaration not necessary, because the efficacy data we used were from previously published studies where confirmation of compliance with the Declaration of Helsinki and Good Clinical Practice had been performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}